3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
49
Immunoglobulin Light-chain Amyloidosis
6
Recurrence
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Neoplasm, Residual
3
Lymphoma, Non-Hodgkin
3
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma
2
Smoldering Multiple Myeloma
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Neoplasms, Plasma Cell
1
Lymphoma, T-Cell, Peripheral
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Carcinoma, Non-Small-Cell Lung
1
Autoimmune Diseases of the Nervous System
1
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
Anemia, Aplastic
1
Amyloidosis
1
Acute Kidney Injury
1
Interventions
fludarabine
3
Cyclophosphamide
3
ofatumumab
1
daratumumab
1
Alleles
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Autoimmune Diseases of the Nervous System
×
daratumumab
×
Clear all
NCT06867991
2025-07-15
RADIA
The First People's Hospital of Changzhou
Phase 3
Recruiting
200 enrolled